Clinical Trial Update: HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) [Phase 3]

View source ↗

Summary

HELIOS-A, a Phase 3 study of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR) has completed and posted results on 2022-08-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin Amyloidosis
• Transthyretin Amyloidosis

Drugs mentioned

• AMVUTTRA (VUTRISIRAN)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Amyloidosis, Hereditary, Transthyretin Amyloidosis | Phase 3 | Status: COMPLETED | Results posted: 2022-08-11